skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Vadimezan (Code C2504)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Vadimezan

Definition: A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.

NCI-GLOSS Definition: An anticancer drug that is a type of angiogenesis inhibitor.

Display Name: Vadimezan

Label: Vadimezan

NCI Thesaurus Code: C2504 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2930490  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
5,6-Dimethylxanthenone-4-Acetic Acid
Dimethyloxoxanthene Acetic Acid
dimethylxanthenone acetic acid
Dimethylxanthenone Acetic Acid

External Source Codes: 
CAS Registry Number 117570-53-3 (see NLM ChemIDplus info)
FDA UNII Code 0829J8133H
NSC Code 640488 (see NCI DTP info)
PDQ Closed Trial Search ID 43320
PDQ Open Trial Search ID 43320 (check for NCI PDQ open clinical trial info)
UMLS CUI C2930490

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C17H14O4
code C2504
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Dimethylxanthenone_Acetic_Acid
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom